Aug 28, 2015 at 11:53 | Source: Reuters
While the Bank of Japan has said it will look through the effect of slumping oil costs on inflation, the weak figures will keep it under pressure to expand its massive stimulus programme.
Aug 25, 2015 at 16:36 | Source: CNBC
Earlier in the session, the Tokyo bourse had staged a comeback, alongside most of the other regional stock indices, on the back of bargain hunting in beaten-down stocks and as the Dow Jones Industrial Average futures opened up more than 100 points Monday evening in the US.
Aug 25, 2015 at 08:58 | Source: Reuters
Aso said that while there was no immediate plan for G20 and G7 nations to take coordinated action against the current markets turmoil, global financial authorities were in frequent contact with each other on market developments.
Aug 19, 2015 at 14:05 | Source: Moneycontrol.com
BoAML is betting big on Indian pharma companies as weak rupee is positive for the sector. It says Cadila, Aurobindo and Lupin are the biggest beneficiaries of a weak rupee while Sun Pharma would see a moderate impact as it has global operations.
Aug 11, 2015 at 17:16 | Source: Moneycontrol.com
Revenue met expectations, growing 10 percent to Rs 6,767.6 crore in June quarter compared to Rs 6,157 crore in March quarter.
Aug 10, 2015 at 12:01 | Source: CNBC-TV18
According to average of estimates of analysts polled by CNBC-TV18, net profit is seen rising 0.6 percent sequentially to Rs 894 crore and revenue may increase 1.7 percent to Rs 6,262 crore in the quarter ended June.
Aug 07, 2015 at 12:00 | Source: Moneycontrol.com
Sun Pharma gained nearly a percent as Taro's first quarter net sales jumped 65 percent and margin expanded by 2070 basis points to 62.5 percent. Profits more than doubled to USD 104 million.
Aug 07, 2015 at 09:56 | Source: Moneycontrol.com
Revenue grew by 65 percent to USD 215 million compared to USD 130.2 million year-on-year. The NYSE-listed company said revenue in Q1FY15 was negatively impacted by a USD 79 million provision for price protection. June quarters price protection provision was USD 14 million, it added.
May 29, 2015 at 19:18 | Source: CNBC-TV18
Sarabjit Kour Nangra, VP- Research, Angel Broking, believes it to be the Ranbaxy effect. However, she says 14.5 percent is very low, because after consolidation she was looking at closer to 30 percent.
May 27, 2015 at 12:26 | Source: Moneycontrol.com
Taro Pharmaceutical Industries's fourth quarter net income grew by 70 percent to USD 152.3 million compared to USD 89.6 million in the year-ago period. Higher revenue, operational performance and forex income helped the bottomline.
Messages on Taro »


Platinum Member


Ranbaxy Labs  

One must understand that SUN cannot b redflagged bcs its main subsidiary is TARO is situated in Iserael which has more strintest practoces more than even USA.Also USA realised that by redflagging Indian cos like RBaxy it is USA public which is suffering bcs of nongen drugs produced by another

6.26 PM Jul 7th 2014


Platinum Member


Suven Life Scie  

That`s also a good strategy.Something I hear/read,even RJ follows.SLS management is conservative & Mr. Jasti has always been very candid about his company.Recently,they had achieved aprroval for Malathion,to be marketed by Taro.The bottomline will be 2MUSD every year from this product alone! See

9.23 PM Jul 3rd 2014


Silver Member


Sun Pharma  

Ultimately patience is paying rich dividends. Good to know Taro has shot up by more than 16%. Sun should open with a big gap monday morning. Cheers!

8.49 PM Jun 28th 2014


Gold Member


Sun Pharma  

Awsome Taro....16% up at 137 !! good news coming for sun pharma as well !!

6.53 PM Jun 28th 2014


Gold Member


Sun Pharma  

dear kurken...its other way buddy they will acquire mnc`s like taro,caraco,dusa etc...list not going to stop and its a professionally managed company...stay invested...

10.27 AM May 30th 2014


New Member



Guys: Hope you got benefitted by my buy call on Lupin today... all the pharma stocks buzzing Dr. Reddy, Lupin, Div lab... tomorrow sun pharma likely to post good results.. so continue buy Lupin as near term target is 960. Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro

4.06 PM May 28th 2014


New Member


Sun Pharmaceutical Industries  

Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro Pharma contributes near 48% of US revenue and 29% of total revenue. Sharekhan expect Sun Pharma to report a revenue of Rs4290 crore (39.7% YoY)and net profit of Rs1313 crore (29.8% YoY) in Q4FY2014. Sharekhan can expect

4.03 PM May 28th 2014

Sun Pharma  

Taro EPS up 44% for FY.

2.43 PM May 28th 2014

Sun Pharma  

Net income attributable to Taro was $360.4 million compared to $266.2 million, a $94.2 million increase, resulting in diluted earnings per share of $8.14 compared to $5.95 Net sales of $759.3 million, increased $88.3 million, or 13.2%, with a slight decrease in volumes Taro`s FY 14 results. EPS

2.42 PM May 28th 2014


New Member


Sun Pharma  

Taro posted spectacular results this time around. Sun Pharma will also post good results tomorrow. Exporters are doing good currently, so it is a good idea to buy sun pharma today, a combination of good results and short covering on expiry can easily take this stock to 600 levels. 580 can be used

1.54 PM May 28th 2014

News across the web »
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.